Anonymous
Guest
Anonymous
Guest
Sucampo's Lubiprostone meets primary endpoint in Phase 3 clinical trial for OBD
Sucampo's Lubiprostone meets primary endpoint in Phase 3 clinical trial for OBD
Sucampo's Lubiprostone meets primary endpoint in Phase 3 clinical trial for OBD
What a waste of development dollars, although I am sure Sucampo will receive a hefty milestone payment from Takeda. This trial has zero commerical value, it provides no new value to Amitiza in the market place and doctors and managed care will ignore it utterly. Another sign of a Takeda leadership that is completely lost.